1. Home
  2. OTH vs LUNG Comparison

OTH vs LUNG Comparison

Compare OTH & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

OTH

Off The Hook YS Inc.

N/A

Current Price

$2.59

Market Cap

67.2M

Sector

Industrials

ML Signal

N/A

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.54

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OTH
LUNG
Founded
2012
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Marine Transportation
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.2M
72.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
OTH
LUNG
Price
$2.59
$1.54
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$6.81
AVG Volume (30 Days)
33.3K
376.4K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
10.00
EPS
N/A
N/A
Revenue
N/A
$83,789,000.00
Revenue This Year
N/A
$9.21
Revenue Next Year
N/A
$5.03
P/E Ratio
$600.18
N/A
Revenue Growth
N/A
22.01
52 Week Low
$1.95
$1.31
52 Week High
$3.75
$8.71

Technical Indicators

Market Signals
Indicator
OTH
LUNG
Relative Strength Index (RSI) 48.76 43.56
Support Level $2.03 $1.51
Resistance Level $2.72 $1.93
Average True Range (ATR) 0.20 0.10
MACD 0.00 0.03
Stochastic Oscillator 74.20 49.18

Price Performance

Historical Comparison
OTH
LUNG

About OTH Off The Hook YS Inc.

Off The Hook YS Inc operates as a nationwide leader in the yacht and boat dealership industry, offering a comprehensive suite of services that spans the entire boat value chain. The company operates as two segments: Boat Sales and Azure Funding. Boat Sales includes Specializing in the buying, selling, and wholesaling of yachts and boats, having a boat dealership created to run Yellow Fin sales in Miami; and Azure Funding includes a recreational loan broker and lender providing financing solutions for individuals, dealerships, and brokerages.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: